Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:13 am
Author: Getaka|Social: XLinkedIn

Krebs Biochemicals & Industries Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹136.97Undervalued by 208.49%vs CMP ₹44.40

P/E (15.0) × ROE (15.0%) × BV (₹74.60) × DY (2.00%)

Defaults: P/E=15, ROE=15%

₹149.59Undervalued by 236.91%vs CMP ₹44.40
MoS: +70.3% (Strong)Confidence: 28/100 (Low)Models: 1 Under, 1 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹221.4163%Under (+398.7%)
Revenue MultipleRevenue₹29.8938%Over (-32.7%)
Consensus (2 models)₹149.59100%Undervalued
Key Drivers: EPS CAGR 61.7% lifts DCF — verify sustainability.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 61.7% · Defaults: P/E=15, ROE=15%

*Investments are subject to market risks

Investment Snapshot

54
Krebs Biochemicals & Industries Ltd scores 54/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health43/100 · Moderate
ROCE 30.1% ExcellentROE 0.0% WeakD/E -2.35 Low debtInterest Coverage 0.0x RiskyProfitable 0/5 years Inconsistent
Smart Money50/100 · Moderate
FII holding stable No changePromoter holding at 72.7% Stable
Earnings Quality75/100 · Strong
OPM expanding (-44% → -26%) ImprovingWorking capital: -787 days (improving) Efficient
Quarterly Momentum45/100 · Moderate
Revenue (4Q): -53% YoY DecliningOPM: 4.1% (up 45.2% YoY) Margin expansion
Industry Rank55/100 · Moderate
ROCE 30.1% vs industry 16.4% Above peers3Y sales CAGR: -11% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:13 am

Market Cap 95.8 Cr.
Current Price 44.4
Intrinsic Value₹149.59
High / Low 114/38.3
Stock P/E
Book Value 74.6
Dividend Yield0.00 %
ROCE30.1 %
ROE%
Face Value 10.0
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Krebs Biochemicals & Industries Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lactose (India) Ltd 106 Cr. 84.2 137/76.021.9 49.60.00 %12.9 %9.69 % 10.0
MPS Pharmaa Ltd 3.15 Cr. 1.65 3.17/1.57 0.330.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 2,692 Cr. 247 479/22256.3 24.30.27 %27.3 %21.7 % 1.00
Gujarat Terce Laboratories Ltd 25.3 Cr. 32.5 68.4/29.0 10.10.00 %41.4 %14.6 % 10.0
Gujarat Inject (Kerala) Ltd 120 Cr. 82.1 82.1/17.0481 6.930.00 %13.5 %11.0 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Krebs Biochemicals & Industries Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 9.0911.4610.5814.8912.9811.9712.8912.8611.476.105.484.177.27
Expenses 12.0716.0813.2015.7915.0715.0915.0815.5816.1811.517.576.976.97
Operating Profit -2.98-4.62-2.62-0.90-2.09-3.12-2.19-2.72-4.71-5.41-2.09-2.800.30
OPM % -32.78%-40.31%-24.76%-6.04%-16.10%-26.07%-16.99%-21.15%-41.06%-88.69%-38.14%-67.15%4.13%
Other Income 0.020.190.040.170.030.210.030.090.250.340.010.010.00
Interest 0.901.031.101.131.191.271.321.421.561.611.651.731.79
Depreciation 1.691.481.651.711.731.671.691.711.721.571.601.621.63
Profit before tax -5.55-6.94-5.33-3.57-4.98-5.85-5.17-5.76-7.74-8.25-5.33-6.14-3.12
Tax % 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.24%0.00%0.00%0.00%
Net Profit -5.55-6.94-5.33-3.57-4.98-5.85-5.17-5.76-7.74-8.27-5.32-6.14-3.13
EPS in Rs -2.57-3.22-2.47-1.66-2.31-2.71-2.40-2.67-3.59-3.84-2.47-2.85-1.45

Last Updated: March 4, 2026, 3:16 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 7:46 pm

MetricSep 2014n n 15mMar 2015n n 6mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales -0-013344833546052504323
Expenses 451411415852719468595833
Operating Profit -4-5-12-8-8-10-19-18-34-16-9-15-10
OPM % -1,088%-248%-22%-20%-56%-33%-57%-30%-17%-35%-43%
Other Income 031-0-100111010
Interest 0413566653567
Depreciation -0244445567776
Profit before tax -4-8-16-16-18-20-29-28-45-25-20-27-23
Tax % 10%-0%-0%-0%-0%-0%-0%-0%-0%-0%-0%0%
Net Profit -4-8-16-16-18-20-29-28-45-25-20-27-23
EPS in Rs -3.78-6.82-10.33-9.67-10.73-12.03-16.04-14.45-20.65-11.45-9.15-12.50-10.61
Dividend Payout % -0%-0%-0%-0%-0%-0%-0%-0%-0%-0%-0%-0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)0.00%-12.50%-11.11%-45.00%3.45%-60.71%44.44%20.00%-35.00%
Change in YoY Net Profit Growth (%)0.00%-12.50%1.39%-33.89%48.45%-64.16%105.16%-24.44%-55.00%

Krebs Biochemicals & Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:5%
3 Years:-10%
TTM:-32%
Compounded Profit Growth
10 Years:%
5 Years:1%
3 Years:12%
TTM:-38%
Stock Price CAGR
10 Years:-1%
5 Years:-4%
3 Years:-19%
1 Year:-15%
Return on Equity
10 Years:%
5 Years:%
3 Years:%
Last Year:%

Last Updated: September 5, 2025, 9:20 am

Balance Sheet

Last Updated: December 10, 2025, 2:59 am

MonthSep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 10101314141718202222222222
Reserves -69-0-12-32-31-43-62-97-121-141-168-179
Borrowings 93613148565366111143183194212219
Other Liabilities 4129737387103939112291104103106
Total Liabilities 138108116122126142134159190175178169168
Fixed Assets 585893102101101105118139147150146146
CWIP 001144341284231
Investments 0000000000000
Other Assets 80501316213824294324262020
Total Assets 138108116122126142134159190175178169168

Reserves and Borrowings Chart

Cash Flow

MonthSep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 49-45-15-11-64-36-15-17-252-8
Cash from Investing Activity + 0-3-4-5-3-4-10-23-23-13-8-5
Cash from Financing Activity + -4954131691729384037613
Net Cash Flow 06-6-0017-171-1-000
Free Cash Flow 49-48-23-17-9-1-45-40-41-36-5-11
CFO/OP -1,225%924%123%140%83%-40%191%83%51%157%-27%52%

Free Cash Flow

MonthMar 2015n n 6mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2014n n 15m
Free Cash Flow-5.00-43.00-56.00-64.00-63.00-85.00-129.00-177.00-199.00-203.00-227.00-4.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthSep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 101803222254140
Inventory Days 14,7042,162337142345234230170543396
Days Payable 32,2504,3605103395212923402171,0511,192
Cash Conversion Cycle -17,536-2,018-170-175-174-57-106-44-494-795
Working Capital Days -6,532-2,132-275-315-267-187-261-232-322-787
ROCE %-4%-8%-26%-26%-26%-36%-57%-40%-57%-29%-19%-30%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%
FIIs 0.50%0.50%0.50%0.50%0.50%0.50%0.50%0.50%0.50%0.50%0.50%0.50%
Public 26.76%26.77%26.76%26.77%26.75%26.75%26.76%26.76%26.75%26.76%26.76%26.76%
No. of Shareholders 9,3159,3939,0308,9908,9098,8489,4259,0918,7989,1188,9128,710

Shareholding Pattern Chart

No. of Shareholders

Krebs Biochemicals & Industries Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) -12.49-9.16-11.30-20.81-14.53
Diluted EPS (Rs.) -12.49-9.16-11.30-20.81-14.53
Cash EPS (Rs.) -9.39-6.01-8.41-17.73-11.84
Book Value[Excl.RevalReserv]/Share (Rs.) -67.83-55.29-46.13-34.83-21.78
Book Value[Incl.RevalReserv]/Share (Rs.) -67.83-55.29-46.13-34.83-21.78
Revenue From Operations / Share (Rs.) 20.0923.3924.1827.6927.37
PBDIT / Share (Rs.) -6.64-3.84-7.03-15.23-8.64
PBIT / Share (Rs.) -9.74-6.97-10.07-18.15-11.25
PBT / Share (Rs.) -12.49-9.15-11.45-20.65-14.45
Net Profit / Share (Rs.) -12.49-9.15-11.45-20.65-14.45
PBDIT Margin (%) -33.06-16.40-29.07-55.00-31.57
PBIT Margin (%) -48.50-29.82-41.65-65.55-41.11
PBT Margin (%) -62.16-39.12-47.36-74.58-52.80
Net Profit Margin (%) -62.19-39.12-47.36-74.58-52.80
Return on Capital Employeed (%) -32.07-12.92-17.25-35.02-19.88
Return On Assets (%) -15.93-11.07-14.11-23.45-17.81
Long Term Debt / Equity (X) -0.21-0.44-0.43-0.03-2.35
Total Debt / Equity (X) -0.56-0.53-0.53-0.17-2.35
Asset Turnover Ratio (%) 0.240.280.280.340.36
Current Ratio (X) 0.090.280.320.450.44
Quick Ratio (X) 0.040.120.080.120.09
Inventory Turnover Ratio (X) 5.470.490.812.191.62
Interest Coverage Ratio (X) -2.42-1.76-5.10-6.09-2.70
Interest Coverage Ratio (Post Tax) (X) -3.56-3.21-7.30-7.26-3.52
Enterprise Value (Cr.) 356.07324.85304.75451.99274.16
EV / Net Operating Revenue (X) 8.226.445.857.575.11
EV / EBITDA (X) -24.86-39.27-20.10-13.76-16.17
MarketCap / Net Operating Revenue (X) 3.322.612.335.183.25
Price / BV (X) -0.98-1.10-1.22-4.12-4.08
Price / Net Operating Revenue (X) 3.322.612.335.183.25
EarningsYield -0.18-0.14-0.20-0.14-0.16

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Krebs Biochemicals & Industries Ltd. is a Public Limited Listed company incorporated on 02/12/1991 and has its registered office in the State of Andhra Pradesh, India. Company's Corporate Identification Number(CIN) is L24110AP1991PLC103912 and registration number is 103912. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 43.31 Cr. and Equity Capital is Rs. 21.56 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsKothapalli Village, Kasimkota Mandal, Anakapalli Dist. Andhra Pradesh 531031Contact not found
Management
NamePosition Held
Dr. R T RaviChairman & Non-Exe.Director
Mr. Manish Kumar JainManaging Director & CEO
Mr. P K BhattacharyyaNon Executive Director
Mr. Avinash RaviNon Executive Director
Mr. P M KathariyaIndependent Director
Ms. Dipti ShahIndependent Director
Mr. Satya Prakash ChigurupatiIndependent Director
Mr. Sumanth KarlapudiIndependent Director

FAQ

What is the intrinsic value of Krebs Biochemicals & Industries Ltd and is it undervalued?

As of 19 April 2026, Krebs Biochemicals & Industries Ltd's intrinsic value is ₹149.59, which is 236.91% higher than the current market price of ₹44.40, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (%), book value (₹74.6), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Krebs Biochemicals & Industries Ltd?

Krebs Biochemicals & Industries Ltd is trading at ₹44.40 as of 19 April 2026, with a FY2026-2027 high of ₹114 and low of ₹38.3. The stock is currently near its 52-week low. Market cap stands at ₹95.8 Cr..

How does Krebs Biochemicals & Industries Ltd's P/E ratio compare to its industry?

Krebs Biochemicals & Industries Ltd has a P/E ratio of , which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Krebs Biochemicals & Industries Ltd financially healthy?

Key indicators for Krebs Biochemicals & Industries Ltd: ROCE of 30.1 % indicates efficient capital utilization; ROE of % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Krebs Biochemicals & Industries Ltd profitable and how is the profit trend?

Krebs Biochemicals & Industries Ltd reported a net profit of ₹-27 Cr in Mar 2025 on revenue of ₹43 Cr. Compared to ₹-45 Cr in Mar 2022, the net profit shows a mixed trend.

Does Krebs Biochemicals & Industries Ltd pay dividends?

Krebs Biochemicals & Industries Ltd has a dividend yield of 0.00 % at the current price of ₹44.40. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Krebs Biochemicals & Industries Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports